Back to top

The Zacks Analyst Blog Highlights: Oracle, Intuit, Regeneron, Macy's and Deere

Read MoreHide Full Article

 

For Immediate Release

Chicago, IL –August 29, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oracle (ORCL - Free Report) , Intuit (INTU - Free Report) , Regeneron Pharmaceuticals (REGN - Free Report) , Macy's (M - Free Report) and Deere (DE - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for Oracle, Inuit and Regeneron

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle, Intuit and Regeneron Pharmaceuticals. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

Oracle’s shares have underperformed the Zacks Computer Software industry so far this year, gaining +4.4% vs. +24.7%. However, Oracle is one of the largest enterprise-grade database, middleware and application software providers.

The company is benefiting from strong adoption of its cloud-based solutions. The Zacks analyst believes that the company’s growing cloud market share will continue to drive top-line growth in the long haul. The analyst notes that partnerships with the likes of Accenture are helping the company rapidly expand its cloud-base clientele.

Also, anticipated strong demand for the next-generation autonomous database supported by machine learning will boost competitive position against AWS. Nonetheless, stiff competition in the cloud is expected to hurt margins and will make revenue growth difficult.

Notably, Oracle has undergone structural changes. It no longer intends to break out its cloud revenues and does not provide any guidance on SaaS, Cloud PaaS and IaaS. This move is likely to enhance investor concern about the company's outlook.

Buy-rated Intuit’s shares have outperformed the Zacks Computer Software industry over the last year, increasing +53.6% vs. a gain of +37.8%.  Intuit’s fiscal Q4 results were driven by impressive growth across its Small Business and Self-Employed, and Consumer Tax segments.

Intuit is benefiting from frequent product refreshes, which help it to gain customers. It witnessed solid growth in QuickBooks Online subscriber base. TurboTax Live offering also is likely to be a tailwind to the Consumer tax business.

Moreover, the company’s strategy of shifting its business to cloud-based subscription model will help generate more stable revenues over the long run. However, high costs and expenses remain a major concern.

Competition from companies like Microsoft also increases pricing pressure. Again, due to the business being seasonal, Intuit is exposed to significant operational risks.

Buy-rated Regeneron’s shares have outperformed the Zacks Biomedical and Genetics industry year-to-date, gaining +3.3% vs. a decline of -4%. Regeneron’s second-quarter results were impressive as the company comfortably beat both earnings and sales estimates on the back of growth in Dupixent’s sales.

Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. The performance of Regeneron's key growth driver, Eylea, continues to be strong as well and the recent label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales.

The company is also working to expand Dupixent’s label, which should diversify the company’s revenue base and reduce dependence on Eylea. Immuno-oncology candidate cemiplimab’s progress is promising as well and a potential approval for the treatment of cutaneous squamous cell carcinoma in October will be a significant boost for Regeneron.

Other noteworthy reports we are featuring today include Macy's and Deere.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

http://www.zacks.com                                                   

 Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like